




Deucravacitinib

Revised: November 15, 2023.

CASRN: 1609392-27-9



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of deucravacitinib during breastfeeding. Because it is more than 80% bound to plasma proteins, the amount in milk is likely to be low. However, it is well absorbed orally. If deucravacitinib is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Psoriasis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Phototherapy, Tretinoin

Substance Identification

Substance Name

Deucravacitinib

CAS Registry Number

1609392-27-9

Drug Class

Breast Feeding

Lactation

Milk, Human

Dermatologic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Tyrosine Kinase Inhibitors

Signal Transduction Inhibitors

Janus Kinase Inhibitors

JAK Inhibitors